Of course your competent? doctor already knew about this way back in 2005, and got research initiated. NO? So you don't have a functioning stroke doctor, do you?
Reactive oxygen species and the modulation of stroke June 2005
The latest here:
Nanozymes: Potential Therapies for Reactive Oxygen Species Overproduction and Inflammation in Ischemic Stroke and Traumatic Brain Injury
- Yunfan Yang
- ,
- Zixiang Li
- ,
- Xiaochong Fan
- ,
- Chao Jiang
- ,
- Junmin Wang
- ,
- Yousef Rastegar-Kashkooli
- ,
- Tom J. Wang
- ,
- Junyang Wang
- ,
- Menglu Wang
- ,
- Nannan Cheng
- ,
- Xiqian Yuan
- ,
- Xuemei Chen*
- ,
- Bing Jiang*
- , and
- Jian Wang*
Abstract
Nanozymes, which can selectively scavenge reactive oxygen species (ROS), have recently emerged as promising candidates for treating ischemic stroke and traumatic brain injury (TBI) in preclinical models. ROS overproduction during the early phase of these diseases leads to oxidative brain damage, which has been a major cause of mortality worldwide. However, the clinical application of ROS-scavenging enzymes is limited by their short in vivo half-life and inability to cross the blood-brain barrier. Nanozymes, which mimic the catalytic function of natural enzymes, have several advantages, including cost-effectiveness, high stability, and easy storage. These advantages render them superior to natural enzymes for disease diagnosis and therapeutic interventions. This review highlights recent advancements in nanozyme applications for ischemic stroke and TBI, emphasizing their potential to mitigate the detrimental effect of ROS overproduction, oxidative brain damage, inflammation, and blood-brain barrier compromise. Therefore, nanozymes represent a promising treatment modality for ROS overproduction conditions in future medical practices.
No comments:
Post a Comment